Atopic Dermatitis Clinical Trial
Official title:
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
NCT number | NCT04287608 |
Other study ID # | R668-AD-1884 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 10, 2021 |
Est. completion date | March 29, 2023 |
Verified date | April 2023 |
Source | Regeneron Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for conjunctivitis events and its effectiveness.
Status | Completed |
Enrollment | 50 |
Est. completion date | March 29, 2023 |
Est. primary completion date | March 29, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Key Inclusion Criteria: - Treatment with DUPIXENT® for AD (per the current US Prescribing Information) should be ongoing, and have been initiated at least 8 weeks prior to study enrollment. NOTE: A single missed dose in the 8 weeks prior to enrollment is allowed. - Patients with protocol-specified conjunctivitis events must present with active bilateral conjunctivitis (with or without cornea or eyelid involvement) diagnosed by the ophthalmologist (investigator) which meets all of the following criteria: - Developed (or significantly worsened) while receiving treatment with DUPIXENT® for AD - Is clinically significant (eg, moderate-to-severe, extensive, persistent, etc) as determined by the investigator - There is a suspected causal relationship between DUPIXENT® and conjunctivitis because: - Conjunctivitis is a new-onset condition or an unusual worsening of a preexisting condition (eg, significantly more severe, more extensive, or more protracted than ever before) AND - No alternative explanation is more plausible, in the opinion of the investigator - Reference patients must have AD treated with current ongoing treatment with DUPIXENT® for equal or longer duration as compared to group 1, with no clinical signs of ocular inflammation noted during the entire DUPIXENT® treatment Key Exclusion Criteria: - Any known medical, social, or personal limitations that are likely to restrict the patient's ability to undergo study visits and complete study procedures (as assessed by the investigator), including hypersensitivity or other contraindications to the anesthetic eye drops used during the ophthalmological examination. NOTE: Other protocol defined inclusion/exclusion criteria apply. |
Country | Name | City | State |
---|---|---|---|
United States | Regeneron Study Site | Baltimore | Maryland |
United States | Regeneron Study Site | Boston | Massachusetts |
United States | Regeneron Study Site | Dallas | Texas |
United States | Regeneron Study Site | Great Neck | New York |
United States | Regeneron Study Site | Houston | Texas |
United States | Regeneron Study Site | Irvine | California |
United States | Regeneron Study Site | Memphis | Tennessee |
United States | Regeneron Study Site | Miami | Florida |
United States | Regeneron Study Site | New Orleans | Louisiana |
United States | Regeneron Study Site | New York | New York |
United States | Regeneron Study Site | Palo Alto | California |
United States | Regeneron Study Site | Pasadena | California |
United States | Regeneron Study Site | Philadelphia | Pennsylvania |
United States | Regeneron Study Site | Pittsburgh | Pennsylvania |
United States | Regeneron Study Site | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Regeneron Pharmaceuticals | Sanofi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline Ophthalmologist Diagnosis | Diagnosis includes: symptoms and morphological features of conjunctivitis | Initial Visit (Day 1) | |
Primary | Proportion of patients in each category of ophthalmologist diagnoses | Symptoms / Morphological features | Initial Visit (Day 1) | |
Primary | Proportion of patients with symptoms | Symptoms include but are not limited to: infection, dry eye, cytological shifts, etc | Initial Visit (Day 1) up to week 52 | |
Primary | Proportion of patients with morphological features | Morphological features include but are not limited to: bulbar redness, limbal redness, lid redness, lid roughness, etc. and associated conditions may include blepharitis, keratitis, etc. | Initial Visit (Day 1) up to week 52 | |
Primary | Proportion of conjunctivitis events by severity | Severity is based on the nature of the event, intensity of signs and/or symptoms, current functional impairment, and potential long-term health hazards related to the event. 3-point scale: Mild, Moderate or Severe. | Initial Visit (Day 1) up to week 52 | |
Primary | Duration of conjunctivitis event(s) in patients whose conjunctivitis resolved | Up to week 52 | ||
Primary | Proportion of patients with conjunctivitis event resolution | Up to week 52 | ||
Primary | Proportion of patients who discontinued DUPIXENT® due to conjunctivitis events | Up to week 52 | ||
Primary | Ophthalmologists assessment of treatment effectiveness, overall and by clinical phenotype based on a 5-point scale. | Treatment Effectiveness assessed on a 5-point scale: Poor, Fair, Good, Very Good, Excellent | Up to week 52 | |
Primary | Change in eosinophil counts and other cells identified by impression cytology from the conjunctival tissue | Measured by conjunctival impression sample (EyeprimTM) for cytology and RNA sequencing | Up to week 52 or resolution |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |